贝塔阻断剂在内和间透析性高血压患者的疗效:系统性审查和元分析
Eugenia Maria Alodia Hartono1, Felicia Fransisca Saputra2, Angeline Asti Shiela Permata2
1Faculty of Medicine, University of Gadjah Mada, Yogyakarta, Indonesia. alodiahartono89@gmail.com.
International urology and nephrology
|February 29, 2024
概括
贝塔抑制剂在血液透析患者中有效降低缩血压,这些患者经历了透析内和透析间的高血压. 这项研究证实了它们在透析期间和透析期间控制血压波动的作用.
科学领域:
- 脏病学和高血压的研究
- 临床药理学 临床药理学
背景情况:
- 内透析性高血压影响5-15%的血液透析患者,往往与更高的内透析性血压相关.
- β抑制剂因其在血压控制,心血管事件减少和内皮功能改善方面的有效性而受到青.
研究的目的:
- 分析β阻塞剂在内和内透析性高血压患者中的抗高血压作用.
- 为了评估β阻塞剂在血液透析期间和两次透析期间控制血压波动的有效性.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 包括从多个数据库 (PubMed,Cochrane,Scopus) 来源的2008-2023年的全文临床试验和RCT.
- 分析了七篇符合条件的文章,并对内透析 (4项研究,82名参与者) 和内透析 (5项研究,142名参与者) 高血压进行了子组分析.
主要成果:
- 贝塔阻断剂的干预导致静脉压 (SBP) 显著降低,用于日内透析性高血压 (平均差异:15.19 mmHg,P < 0.00001).
- 在透析前和透析后使用β-阻断剂治疗内透析性高血压期间,SBP保持稳定 (平均差异:-2.72 mmHg,P = 0.29).
- 从治疗透析间高血压前至治疗后观察到SBP显著降低 (平均差异:-10.92 mmHg,P < 0.0001).
结论:
- 贝塔阻断剂治疗显著降低了静脉压在血液透析患者内和内透析高血压.
- 这些发现支持使用β阻塞剂在透析患者的综合血压管理.
相关概念视频
Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
Adrenergic Antagonists: ɑ and β-Receptor Blockers
447
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
447
Antihypertensive Drugs: Types of β-Blockers
678
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
678
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
801
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
801
Antihypertensive Drugs: Action of β1 Blockers
447
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
447
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429


